Serbia receives Paxlovid anti-COVID-19 drug manufactured by US drug company Pfizer. The first batch of this antiviral drug arrived in the country this morning and distribution began at the Health Centers, announced the Serbian Ministry of Health.
“Paxlovid is an antiviral medicine containing the ingredients ritonavir and nirmatrelvir, intended for oral use and indicated for the treatment of COVID-19 infection in adults who are at increased risk of developing a severe clinical picture. It is recommended that “within the first five days of the onset of symptoms,” the Serbian ministry said in a statement.
Two other anti-coronavirus drugs are used in Serbia. These are the Chinese Favipiravir that has been administered to patients with COVID since July 2021 and the American drug Merck that arrived in December 2021.
The outbreak of the coronavirus pandemic in Serbia confirmed 1,779,782 cases, while 14,054 patients died from complications of Sars-Cov2 disease.
The mortality rate is 0.79%.
SOURCE: ΑΠΕ-ΜΠΕ
Source: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
